Information about Cinryze (C1 Esterase Inhibitor)
Cinryze is a prescription medication used to manage Hereditary Angioedema (HAE), a rare genetic disorder that leads to episodes of severe swelling in various parts of the body. It is derived from human plasma and contains a C1 esterase inhibitor, a protein that helps control inflammatory responses and prevents excessive swelling.
Product Highlights
- Prevention of recurrent angioedema attacks in patients with Hereditary Angioedema (HAE).
- Management of acute episodes of angioedema in patients with HAE.
Key Ingredient
Key Benefits
- Helps to decrease the number of angioedema episodes.
- Provides relief from the symptoms of acute angioedema attacks.
- By preventing and managing swelling episodes, it improves overall well-being and daily functioning for patients with HAE.
Direction of Use
- Administered intravenously, typically every 3 to 4 days, depending on the patient's condition and the frequency of angioedema attacks.
- Administered intravenously at the onset of an angioedema attack or as prescribed by a healthcare provider.
Safety Concerns
- Risk of hypersensitivity reactions, including anaphylaxis. Patients should be monitored during and after administration.
- As the product is derived from human plasma, there is a potential risk of transmitting infections, though rigorous screening is performed.
- Rarely, thromboembolic events (such as blood clots) may occur, so careful monitoring is required for patients with a history of such conditions.
Avoid Cinryze (C1 Esterase Inhibitor) If
- You have a known allergy or hypersensitivity to Cinryze or any of its components.
- You have an acute viral or severe infection, which may warrant caution or alternative treatments.
- Patients with a history of thromboembolic disorders should avoid Cinryze unless the benefits outweigh the risks and under close medical supervision.
